ChroMedX Commences AUF Development with Aline Inc. and Spectrum Labs

December 9, 2014
Toronto, Ontario

ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of ALine Inc. as primary contractor for the development of its recently acquired Automated Ultrafiltration (AUF) Cartridge.

The AUF cartridge will be used as part of an automated system in the preparation of plasma/serum samples for immunoassay or mass spectrometry analysis of free hormones and free therapeutic drugs.  Currently samples must be centrifuged, a time consuming, manual process, to remove proteins, which interfere with the immunoassay for these species, from the plasma sample.    As there is no existing comparable method for sample preparation, the AUF has the potential to be a disruptive technology for this analytical segment.

ALine, with the collaboration of ultrafiltration membrane manufacturer Spectrum Labs of Rancho Dominguez, CA will work together to define operating parameters, create a working prototype cartridge and finally produce a limited pre-production quantity for clinical testing by early Q3 2015.

Aline, which is already the lead contractor for the Company’s HemoPalm system, has expertise in the engineering, prototyping and manufacturing of microfluidic cartridges used in the life sciences and in vitro diagnostic fields. ALine Inc. was founded by President and CEO, Leanna Levine, Ph.D.  In particular, Dr. Levine has specific experience in ultrafiltration technology from past positions at both Monsanto and with project collaborator Spectrum Labs.

“We are pleased with the confidence that ChroMedX has shown in ALine, to award us the AUF project.  The AUF will be a significant step forward in the preparation of plasma/serum samples for immunoassay and mass spectrometry analysis, allowing physicians to make a more accurate clinical assessment of a patient in the context of abnormal levels of hormones, and therapeutic levels as well as toxic levels of drugs in a patient’s blood ”, said ALine President Leanna Levine.

Spectrum Laboratories develops and manufactures innovative products for bioseparation and ultrafiltration.   Spectrum products are used for the filtration, isolation, purification and concentration of pharmaceuticals, diagnostics, food, beverages and industrial fluids.

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing.  The devices are protected by the Company’s issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:

Website: www.ChroMedX.com

Facebook: facebook.com/ChroMedXcorp

Twitter: www.twitter.com/ChroMedXcorp

Investor Enquiries:

W. Clark Kent
Corporate Development
647-519-2646
ckent@ChroMedX.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law.   Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur.   Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE.   There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control.   The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law.   The reader is cautioned not to place undue reliance on forward-looking statements.   Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com